R
Roopinder Gillmore
Researcher at Royal Free London NHS Foundation Trust
Publications - 61
Citations - 3428
Roopinder Gillmore is an academic researcher from Royal Free London NHS Foundation Trust. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 18, co-authored 52 publications receiving 2548 citations. Previous affiliations of Roopinder Gillmore include Royal Free Hospital & University College London.
Papers
More filters
Journal ArticleDOI
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos,John P. Neoptolemos,Daniel H. Palmer,Daniel H. Palmer,Paula Ghaneh,Eftychia E. Psarelli,Juan W. Valle,Christopher Halloran,Christopher Halloran,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting Ma,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Thilo Hackert,Richard J. Jackson,Markus W. Büchler +36 more
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
Journal ArticleDOI
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Angela Lamarca,Daniel H. Palmer,Harpreet Wasan,Paul Ross,Yuk Ting Ma,Arvind Arora,Stephen Falk,Roopinder Gillmore,Jonathan Wadsley,Kinnari Patel,Alan Anthoney,Anthony Maraveyas,Timothy Iveson,Justin S. Waters,Claire Hobbs,Safia Barber,W David J Ryder,John Ramage,Linda Davies,John Bridgewater,Juan W. Valle +20 more
TL;DR: The ABC-06 clinical trial was a phase 3, open-label, randomised trial done in 20 sites with expertise in managing biliary tract cancer across the UK.
Journal ArticleDOI
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization
Roopinder Gillmore,Sam Stuart,Amy A Kirkwood,Ayshea Hameeduddin,Nick Woodward,Andrew K. Burroughs,Tim Meyer +6 more
TL;DR: When measured at a single, early time point post-therapy, EASL and mRECIST overall response rates are associated with survival and should be used in preference to RECIST 1.1 or target responses.
Journal ArticleDOI
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.
Shao-An Xue,Liquan Gao,Daniel P. Hart,Roopinder Gillmore,Waseem Qasim,Adrian J. Thrasher,Jane F. Apperley,Boris Engels,Wolfgang Uckert,Emma C. Morris,Hans J. Stauss +10 more
TL;DR: In this article, retroviral gene transfer was used to introduce a WT1-specific T-cell receptor (TCR) into T lymphocytes obtained from patients with leukemia and from healthy donors.
Journal ArticleDOI
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Angela Lamarca,Daniel H. Palmer,Harpreet Wasan,Paul Ross,Yuk Ting Ma,Arvind Arora,Stephen Falk,Roopinder Gillmore,Jonathan Wadsley,Kinnari Patel,Alan Anthoney,Anthony Maraveyas,Justin S. Waters,Claire Hobbs,Safia Barber,David Ryder,John Ramage,Linda Davies,John Bridgewater,Juan W. Valle +19 more
TL;DR: Level A evidence supports use of CisGem as first-line chemotherapy for ABC and no robust evidence is available for second- line chemotherapy, but level B evidence is not available.